Current evidence supports integrated, multi-dimensional virological biomarker strategies rather than reliance on single assays to predict pediatric HIV remission. Harmonization, validation in longitudinal pediatric cohorts, ethical feasibility and further research will be critical to identifying and translating these biomarkers for pediatric cure trials.
Reddy et al. (Tue,) studied this question.